Status:
ENROLLING_BY_INVITATION
Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)
Lead Sponsor:
Skripuletz, Thomas Prof. Dr.
Conditions:
Multiple Sclerosis
Clinically Isolated Syndrome (CIS)
Eligibility:
All Genders
18-70 years
Brief Summary
The goal of this observational study is to learn about the role of kappa free light chains (KFLC) in cerebrospinal fluid (CSF) in the diagnosis of multiple sclerosis (MS) and clinically isolated syndr...
Detailed Description
In this multicenter study, paired cerebrospinal fluid (CSF) and serum samples from patients with chronic inflammatory diseases of the central nervous system (multiple sclerosis (MS) / clinically isola...
Eligibility Criteria
Inclusion
- patients diagnosed with multiple sclerosis (MS) or clinically isolated syndrome (CIS) according to 2017-revised McDonald criteria for MS
- age between 18 and 70 years
Exclusion
- no diagnosis of MS or CIS according to 2017-revised McDonald criteria for MS
- no available cerebrospinal fluid (CSF) and serum sample pairs
Key Trial Info
Start Date :
October 27 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
1142 Patients enrolled
Trial Details
Trial ID
NCT07183020
Start Date
October 27 2022
End Date
December 31 2026
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Hochschule Hannover / Hannover Medical School
Hanover, Lower Saxony, Germany, 30625